MG
BMRN icon

Michael Gelband’s BioMarin Pharmaceuticals BMRN Stock Holding History

Michael Gelband’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-44,179
Closed -$2.5M – 1599
2026
Q1 		$2.5M Sell
44,179
-148,173
-77% -$8.64M 0.02% 699
2025
Q4 		$11.4M Buy
+192,352
New +$10.5M 0.09% 221
2025
Q1 		– Sell
-49,817
Closed -$3.27M – 1487
2024
Q4 		$3.27M Sell
49,817
-28,494
-36% -$1.91M 0.02% 562
2024
Q3 		$5.5M Buy
+78,311
New +$6.55M 0.03% 393
2023
Q4 		– Sell
-170,017
Closed -$15M – 1504
2023
Q3 		$15M Sell
170,017
-59,626
-26% -$5.31M 0.14% 147
2023
Q2 		$19.9M Buy
229,643
+51,707
+29% +$4.87M 0.16% 111
2023
Q1 		$17.3M Buy
177,936
+59,730
+51% +$6.19M 0.14% 146
2022
Q4 		$12.2M Sell
118,206
-75,610
-39% -$7.1M 0.18% 132
2022
Q3 		$16.4M Buy
193,816
+82,346
+74% +$7.33M 0.21% 97
2022
Q2 		$9.24M Buy
111,470
+90,341
+428% +$7.19M 0.11% 208
2022
Q1 		$1.63M Sell
21,129
-19,648
-48% -$1.64M 0.02% 885
2021
Q4 		$3.6M Buy
40,777
+32,789
+410% +$2.71M 0.04% 545
2021
Q3 		$617K Buy
+7,988
New +$630K 0.01% 1272
2021
Q2 		– Sell
-16,748
Closed -$1.26M – 2363
2021
Q1 		$1.26M Sell
16,748
-9,706
-37% -$793K 0.02% 787
2020
Q4 		$2.32M Sell
26,454
-13,494
-34% -$1.07M 0.02% 483
2020
Q3 		$3.04M Sell
39,948
-97,708
-71% -$9.89M 0.06% 277
2020
Q2 		$17M Buy
137,656
+126,125
+1,094% +$12.5M 0.44% 26
2020
Q1 		$974K Buy
+11,531
New +$994K 0.05% 314
2019
Q4 		– Sell
-4,600
Closed -$310K – 1540
2019
Q3 		$310K Buy
+4,600
New +$354K 0.01% 861

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Michael Gelband's BMRN Position: Q2 2026 in Review

Michael Gelband sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 44,179 shares — an estimated $2.5M sold.

Michael Gelband first reported a position in BMRN in Q3 2019 and held it in 19 quarters. The position peaked at $19.9M in Q2 2023. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Michael Gelband reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 44,179 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $2.5M.
  • Michael Gelband first reported a position in BioMarin Pharmaceuticals in Q3 2019 and held it in 19 quarters.
  • Michael Gelband's BioMarin Pharmaceuticals position peaked at $19.9M in Q2 2023.
  • 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.